On the heels of a successful $5.5 million Series B round of financing our client, LumiThera, recently unveiled topline, clinical interim data for their LT-300 device! 

In their 30-subject pilot study LumiThera, a clinical stage medical device company focused on developing non-invasive photbiomodulation (PBM) therapies for ocular disorders and disease, proved that PBM (using their LT-300 device) improved the vision of dry AMD patients.

This could be an important option for patients in the near future to counteract the degradation in vision that this disabling disease brings. 

" ... results have demonstrated statistically significant vision benefits in dry AMD patients that were maintained for the 3 month interval,” stated Samuel Markowitz, M.D., Co-Principal Investigator, Department of Ophthalmology and Vision Sciences, University of Toronto. 

For more details and results from the study, please see the full press release. 

Again, a big congrats to the LumiThera team!